Korea Investment CORP Sells 126,006 Shares of Amgen Inc. $AMGN

Korea Investment CORP decreased its position in Amgen Inc. (NASDAQ:AMGN) by 31.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 269,926 shares of the medical research company’s stock after selling 126,006 shares during the period. Korea Investment CORP’s holdings in Amgen were worth $97,746,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. EP Wealth Advisors LLC increased its stake in shares of Amgen by 46.4% during the second quarter. EP Wealth Advisors LLC now owns 70,291 shares of the medical research company’s stock valued at $25,454,000 after buying an additional 22,283 shares during the period. Keebeck Wealth Management raised its stake in Amgen by 4.0% in the second quarter. Keebeck Wealth Management now owns 2,529 shares of the medical research company’s stock worth $916,000 after buying an additional 98 shares in the last quarter. Blue Capital Inc. purchased a new stake in Amgen during the second quarter worth $240,000. Keating Financial Advisory Services Inc. lifted its holdings in Amgen by 7.0% during the second quarter. Keating Financial Advisory Services Inc. now owns 1,289 shares of the medical research company’s stock worth $467,000 after buying an additional 84 shares during the period. Finally, OneAscent Family Office LLC boosted its position in Amgen by 37.6% during the 2nd quarter. OneAscent Family Office LLC now owns 874 shares of the medical research company’s stock valued at $317,000 after acquiring an additional 239 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by company insiders.

Amgen Stock Up 1.3%

NASDAQ:AMGN opened at $439.33 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $443.20. The company has a market cap of $237.51 billion, a PE ratio of 27.30, a P/E/G ratio of 3.13 and a beta of 0.41. The company’s 50 day moving average is $379.03 and its two-hundred day moving average is $361.95.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter last year, the company posted $6.02 earnings per share. The business’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts anticipate that Amgen Inc. will post 22.92 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is 62.65%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on AMGN shares. Weiss Ratings raised Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 6th. Mizuho lifted their target price on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research note on Tuesday. Bank of America lifted their price objective on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada raised their target price on shares of Amgen from $370.00 to $400.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Finally, UBS Group increased their price objective on Amgen from $420.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus price target of $380.43.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Solid operating performance and dividend support the valuation. Amgen’s second-quarter results exceeded expectations, with revenue rising year over year and earnings per share topping consensus. Continued growth and the company’s dividend are helping support investor confidence. Amgen stock holds close to record high as Q2 2026 growth and dividend support valuation
• Positive Sentiment: Analysts raised their outlook. Argus increased its price target to $460 from $375 while maintaining a Buy rating, citing the latest quarterly performance and progress across Amgen’s drug portfolio. Separate reports also highlighted favorable forecasts from Mizuho and Cantor Fitzgerald, reinforcing the bullish analyst sentiment. Amgen gets a fresh target
• Positive Sentiment: Tarlatamab development advanced. Amgen’s Phase 3 DeLLphi-315 study is evaluating a subcutaneous injection of tarlatamab against the current intravenous infusion approach in lung cancer. A successful shot formulation could improve convenience and broaden the commercial potential of the drug. Amgen advances tarlatamab shot versus infusion in Phase 3 lung cancer study
• Positive Sentiment: Trading momentum and options activity were unusually strong. Amgen was identified as a momentum stock after a substantial recent share-price rally, while call-option volume surged well above typical levels, suggesting increased bullish positioning.
• Neutral Sentiment: Valuation is becoming a consideration. With the stock near its recent high and analysts raising targets, some commentary questioned whether much of the favorable news is already reflected in the share price, which could limit near-term upside.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.